Bristol Myers Squibb was among the investors in a series B round announced alongside a collaboration with the small molecule drug developer.
US-based small molecule therapeutics developer Octant Bio has secured $80m in a series B round that included Bristol Myers Squibb (BMS), the pharmaceutical firm with which it recently struck a partnership. Life sciences investment firm Catalio Capital Management led the round, which also featured boutique investment bank Allen & Company and venture capital firms 50…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
